This analysis included 1358 patients from the ASTRONAUT trial, which randomized patients hospitalized for HF with EF ≤40% to aliskiren or placebo in addition to standard care. Patients were stratified by presence of AFF on baseline ECG. NT-proBNP was measured longitudinally by a core laboratory at baseline, 1 month, 6 months, and 12 months. Compared with non-AFF patients, AFF patients experienced greater reduction from baseline in log-transformed NT-proBNP (interaction P < 0.001), but this difference was not significant after adjustment (interaction P = 0.726). The ability of aliskiren to lower NT-proBNP during follow-up differed by AFF status (interaction P = 0.001), with aliskiren lowering NT-proBNP more than placebo among non-AFF patients only. After adjustment, baseline AFF was not associated with mortality or HF hospitalization at 12 months (all P ≥ 0.152).
Introduction
The natriuretic peptide (NP) level is a well-recognized and powerful prognostic tool in heart failure (HF) care.
1 This predictive value is seen across the spectrum of HF care settings, and NP cut-offs are increasingly incorporated into clinical trial selection criteria to identify patients at appropriate risk.
2 -5 These data have sparked enthusiasm regarding the potential of NPs in guiding titration of HF therapy and have prompted inclusion of change in NP as an endpoint in recent HF clinical trials. 3, 6, 7 However, although the prognostic value is supported by robust and consistent evidence, the ability of a change in NP concentration to serve as a reliable surrogate for morbidity and mortality in HF clinical trials remains uncertain. 8 Overall, 30-40% of patients hospitalized for HF (HHF) have co-morbid atrial fibrillation or flutter (AFF), a condition that may contribute to an elevated NP level, independent of HF status. 9 -11 For this reason, in the setting of AFF, a higher NP cut-off for HF diagnosis may be preferred, and some recent trials have specified differing NP inclusion criteria based on presenting rhythm. 7, 9, 12 However, to our knowledge, there are no data systematically evaluating the influence of AFF on longitudinal changes in NP level. Likewise, the hypothesis that the prevalence of AFF in a cohort could influence the ability of an HF trial to meet an NP-defined endpoint remains plausible, but untested. The characterization of such relationships could have significant implications on the use of NP target levels in clinical practice, the design of future HF trials, and the usefulness of an NP trial endpoint. The ASTRONAUT (Aliskiren Trial on Acute Heart Failure Outcomes) trial database affords the opportunity to formally study these questions for the first time. 3 We hypothesized that AFF status would track with a unique longitudinal NP trajectory and that the influence of aliskiren on the NP endpoint would differ by baseline heart rhythm.
Methods

Study design
The study design and primary results of the ASTRONAUT trial have been published previously. 3, 13 Briefly, ASTRONAUT was a prospective, multicentre, global, placebo-controlled randomized trial investigating the effect of aliskiren, a direct renin inhibitor, on clinical outcomes among stable HHF patients. All patients were ≥18 years old with LVEF ≤40%, elevated admission NP level (B-type natriuretic peptide [BNP] ≥400 pg/mL or N-terminal pro-B-type natriuretic peptide [NT-proBNP] ≥1600 pg/mL), and signs and symptoms of fluid overload that required hospitalization. The trial found that aliskiren, compared with placebo, was associated with a sustained significant reduction in longitudinal NT-proBNP without affecting clinical outcomes. ASTRONAUT was conducted in full accordance with the Declaration of Helsinki and with institutional review board and ethics committee approval at all sites. Informed consent was obtained from all patients.
The present analysis included patients in both the aliskiren and placebo study arms. In ASTRONAUT, the presence or absence of AFF at baseline was determined by ECG. To better determine the true influence of rhythm status on longitudinal NT-proBNP and to minimize crossover between study groups during follow-up, patients without AFF on baseline ECG but with history of AFF were excluded from the . Figure 1 details the overall study design and selection of the final analytic cohort.
Natriuretic peptide measurement
The trial protocol specified measurement of NT-proBNP at the time of randomization (i.e. baseline/Visit 2), and 1 month, 6 months, and 12 months post-randomization at a central core laboratory blinded to clinical data. Plasma concentrations of NT-proBNP were measured using the Roche Elecys proBNP assay (Roche Diagnostics GmbH) with a reporting range of 5-35 000 pg/mL. Measurement of NT-proBNP at admission (i.e. screening/Visit 1) was performed locally using the assay of the specific study site and utilized as a study inclusion criterion.
Study endpoints and definitions
The pre-specified endpoints for the present study were (i) change from baseline in log-transformed NT-proBNP at 1, 6, and 12 months; (ii) all-cause death within 12 months; and (iii) the composite of cardiovascular death or HHF (CVM/HHF) within 12 months. All clinical endpoints were adjudicated by a blinded clinical event committee (Brigham and Women's Hospital, Boston, MA, USA). The definition of HHF was presentation requiring overnight hospitalization with signs and symptoms of HF and treatment with intravenous medications (i.e. diuretics, vasodilators, or inotropes), mechanical fluid removal, an intra-aortic balloon pump, or initiation or intensification (i.e. doubling) of the maintenance diuretic dose. Baseline rhythm from a 12-lead ECG was documented by study investigators on the case report form. Aside from heart rate and QRS duration, available ECG documentation fields included atrial fibrillation, atrial flutter, left bundle branch block (LBBB), right bundle branch block (RBBB), pathological Q-waves, left ventricular (LV) hypertrophy, paced rhythm, and other.
Statistical analysis
Eligible patients were grouped by the presence or absence of AFF on baseline ECG. Baseline demographics, vital signs and laboratory values, medical and medication history, and clinical events were compared between groups using 2 , analysis of variance (ANOVA), and Kruskal-Wallis distribution-free tests where appropriate. All continuous variables were reported as mean ± standard deviation or median (interquartile range).
The primary predictor of the present study was AFF status. For assessment of 12-month all-cause death and 12-month CVM/HHF, Kaplan-Meier curves were constructed for each study group and compared using log-rank tests. For clinical endpoints, univariable and multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the primary predictor. The proportional hazards assumption was confirmed by Kolmogorov-type supremum tests.
For NT-proBNP assessment, a mixed effects model with baseline, 1 month, 6 month, and 12 month study visits as repeated measures variables nested in patients was used to analyse AFF status on baseline ECG, study visit, and aliskiren as predictors of log-transformed NT-proBNP. The full information restricted maximum likelihood algorithm was used to estimate model parameters. No data were imputed. Change from baseline in log-transformed NT-proBNP at each time point was estimated separately for patients with and without AFF. For purposes of visual presentation, estimated NT-proBNP values over time were back-transformed to their raw metric (i.e. pg/mL). Due to Figure 1 Selection of the analytic cohort. Potential ECG findings within the non-atrial fibrillation/flutter (AFF) group, as documented on the trial case report form, included the following: LBBB, RBBB, pathological Q-waves, LV hypertrophy, paced rhythm, and 'other'. There was no designation for normal sinus rhythm. eGFR, estimated glomerular filtration rate. * Some patients were excluded for multiple reasons; †ECG findings included in the non-AFF group included 'other' (n = 338), LBBB (n = 209), LV hypertrophy (n = 193), pathological Q-waves (n = 187), paced rhythm (n = 77), and RBBB (n = 62). Individual patients could have multiple ECG findings. a statistically significant interaction between log-transformed change from baseline in NT-proBNP and study treatment, consistent with the overall NT-proBNP results from the main ASTRONAUT trial, a separate multivariable risk-adjusted analysis was performed in placebo patients only. Baseline patient characteristics and their interactions with study visit were used to adjust the estimates for NT-proBNP over time. Quadratic terms of continuous variables were also tested. Interactions with study visit and quadratic terms were not retained if they did not improve model fit by the likelihood ratio test. To evaluate differences in aliskiren treatment effect by AFF status, the influence of aliskiren on change from baseline in NT-proBNP was assessed by three-way interaction (i.e., aliskiren × AFF × study visit).
Multivariable models for clinical outcomes were adjusted for 23 pre-selected baseline covariates: aliskiren treatment, age, gender, ischaemic HF aetiology, NYHA functional class, EF, systolic blood pressure, heart rate, NT-proBNP, serum sodium, serum blood urea nitrogen, QRS duration, medical history (prior HHF, hypertension, CAD, diabetes, COPD), and background therapy [ACE inhibitor/ARB, beta-blocker, mineralocorticoid receptor antagonist (MRA), digoxin, implantable cardioverter-defibrillator (ICD), and CRT]. Given the higher number of outcome events, a more expansive list of covariates and interactions could be included in the NT-proBNP multivariable model (see the legend of Figure 3 ). The multiple imputation procedure [fully conditional specification methods as implemented in MI and MIANALYZE procedures in SAS (SAS Institute, Cary, NC, USA)] was used for missing covariate data (<5% for all variables). All statistical analyses were performed using SAS version 9.3 (SAS Institute), and two-tailed P < 0.05 was considered to be statistically significant. 
Results
Patient characteristics
Of the 1615 patients in the ASTRONAUT efficacy cohort, 1358 (84.1%) were included in the present study, of which 492 (36.2%) had baseline AFF ( Figure 1) . Table 1 presents baseline demographic, clinical, and laboratory data for patients by AFF status on baseline ECG. Of patients with baseline AFF, 96.3% had a prior history of AFF. Compared with those without AFF, AFF patients generally had higher baseline NT-proBNP level (median 2805 pg/mL vs. 2645 pg/mL, P = 0.052) and more severe NYHA functional status at admission and randomization. Overall, the use of guideline-directed medical therapy among this population was high, with >80% of patients receiving ACE inhibitors/ARBs and beta-blockers at baseline. However, beta-blocker and digoxin use was higher among AFF patients. Rates of therapeutic anticoagulation were 60.2% and 27.3% in AFF and non-AFF patients, respectively. Baseline ECG data for the non-AFF group are provided in the legend of Figure 1 .
Clinical outcomes
Event rates by AFF status are displayed in Table 2 . Times to first event stratified by AFF status were similar by the Kaplan-Meier method for death (P = 0.537), but significantly different for the composite endpoint with decreased event-free survival among AFF patients (P = 0.035) ( Figure 2 ). Unadjusted and adjusted outcome analyses are presented in Table 3 . Risk of 12-month all-cause death did not significantly differ by AFF status in either unadjusted or adjusted analysis (P ≥ 0.460). Unadjusted estimates of 12-month CVM/HHF demonstrated heightened risk among AFF patients (HR 1.22, 95% CI 1.01-1.46), but this association become non-significant after adjustment (HR 1.16, 95% CI 0.95-1.43).
Atrial fibrillation, aliskiren, and natriuretic peptide trajectory
Within the placebo group, patients with and without baseline AFF had significant reductions in NT-proBNP from baseline to 12 months (P < 0.001 for both groups). AFF patients experienced greater log-transformed reduction from baseline in NT-proBNP (interaction AFF × study visit P < 0.001) ( Table 4 , Figure 3A ), but this difference was not statistically significant after adjustment for patient characteristics (interaction AFF × study visit P = 0.726) ( Figure 3B) .
When including patients from both study treatment arms, the ability of aliskiren to reduce the NT-proBNP level during follow-up differed by AFF status (three-way interaction aliskiren × AFF × study visit P = 0.001) (Figure 4) . Among AFF patients, compared with placebo, aliskiren patients experienced numerically less reduction in NT-proBNP level at 1, 6, and 12 months ( Table 4) , but there were no significant differences in absolute NT-proBNP levels at any time point (Figure 4 ). In contrast, within the non-AFF group, aliskiren patients had numerically larger reductions in NT-proBNP at these same time points, and absolute NT-proBNP concentrations were significantly lower at all post-discharge time points (Figure 4) 
Discussion
In this exploratory analysis of HHF patients with reduced EF, baseline AFF status was associated with distinct clinical profiles but similar risk of post-discharge mortality and HHF after adjustment for patient characteristics. Within the trial's placebo group, AFF was a marker of a distinct NT-proBNP trajectory, with greater reductions in NT-proBNP from baseline to 12 months compared with non-AFF patients. However, after accounting for patient factors, there was no independent influence of AFF status on post-discharge NP trajectory. When patients in both trial arms were considered, the ability of aliskiren to reduce NT-proBNP level over time differed by baseline AFF status. Aliskiren decreased the NT-proBNP level more than placebo in non-AFF patients only, and was associated with significantly lower absolute NT-proBNP concentration at 1-, 6-, and 12-month follow-up. With aliskiren as an illustrative example, we believe these results have implications for future drug development programmes of investigational HF therapies.
To our knowledge, we present the first analysis exploring the influence of AFF on the longitudinal NT-proBNP level. Multiple studies have previously documented the association between AFF and higher NP concentration at a single time point.
10,14,15 Given that NT-proBNP level reflects myocardial stretch and filling pressures, these data supported the intuitive belief that AFF signalled a drop in cardiac performance. 16 Nevertheless, whether AFF is merely a marker or a mediator of higher NT-proBNP level over time remains uncertain. The lack of an independent association between baseline AFF status and NT-proBNP trajectory found here suggests that other patient characteristics (e.g. renal function) tracking with rhythm status may account for differences in A prior post-hoc analysis from ASTRONAUT found no influence of atrial fibrillation on the prognostic value of NT-proBNP concentration at baseline, 1 month, or change from baseline to 1 month. 17 Viewing the ASTRONAUT data in aggregate, there appears to be concordance between (i) a lack of independent association of AFF with longitudinal NT-proBNP level; (ii) a lack of independent association between AFF and clinical outcomes; and (iii) similar ability of the NT-proBNP level to predict clinical outcomes irrespective of rhythm status. Existing data on the prognostic significance of co-morbid AFF in HF patients are mixed, with differential results potentially arising from heterogeneity in study design and populations.
10,18 -20 Notably, although multiple works suggest higher clinical risk with AFF as compared with normal sinus rhythm, the present study adjusted for more prognostic variables than most prior experiences. Moreover, documentation of baseline sinus rhythm was not explicitly required in the ASTRO-NAUT protocol and the present analysis used 'non-AFF' as the comparator group. Thus, the control group of the current study may have included a more heterogeneous collection of rhythms, some of which may have been associated with adverse outcomes and thus attenuated any differences in outcomes between study . a Data represent hazard ratios and 95% confidence intervals for risk of primary co-endpoints for patients with atrial fibrillation/flutter on baseline ECG relative to patients without atrial fibrillation/flutter on baseline ECG. b Adjusted for aliskiren treatment, age, gender, ischaemic heart failure aetiology, NYHA functional class, EF, systolic blood pressure, heart rate, NT-proBNP, serum sodium, serum blood urea nitrogen, QRS duration, medical history (prior hospitalization for heart failure, hypertension, CAD, diabetes, COPD), and background therapy (ACE inhibitor/ARB, beta-blocker, mineralocorticoid receptor antagonist, digoxin, implantable cardioverter-defibrillator, CRT). ACM, all-cause mortality; CVM/HHF, cardiovascular mortality or hospitalization for heart failure. groups. Additionally, exclusion of patients with history of AFF but no AFF at baseline was a notable methodological difference unique to the present study. However, exclusion of these patients, many of whom probably had paroxysmal AFF, probably selected for inclusion of higher risk AFF patients (i.e. increased proportion of persistent/permanent AFF), and thus would not explain similar clinical outcomes between the AFF and non-AFF groups. 21 Despite the influence of AFF on the effect of aliskiren on longitudinal NT-proBNP level, the primary ASTRONAUT results found no interaction between baseline heart rhythm and aliskiren effect on CVM/HHF. 3 The ASTRONAUT data provide a cautionary example of dissociation between NP changes induced by investigational therapies and subsequent clinical outcomes. 22 This stands in contrast to NP changes mediated by evidence-based therapies proven to improve outcomes, where treatment-induced lowering of NT-proBNP may reliably correlate with clinical benefits. 6 Although the ASTRONAUT study design was novel with statistical power to evaluate NT-proBNP and clinical endpoints simultaneously, traditional HF drug development programmes often reserve NP-based outcomes for phase II trials. 7, 23 Had this been the case with the ASTRONAUT data, benefits of aliskiren on NT-proBNP reduction (driven by the non-AFF cohort) would have clearly supported investment towards a definitive phase III trial, a study that would have subsequently disappointed with neutral results.
Mechanistically, it remains unclear why aliskiren was able to cause significant sustained reductions in the NT-proBNP level among non-AFF patients only. From the primary ASTRONAUT trial results, one could speculate that analogous to other experiences with incremental renin-angiotensin-aldosterone system inhibition in HF, aliskiren tends to exert favourable long-term effects on the heart, compatible with long-term reduction in congestion and NT-proBNP. 24, 25 Although the present study showed that AFF patients within the placebo group tended to have greater unadjusted reductions from baseline in NT-proBNP level during follow-up, AFF appeared to negate any potential additive NT-proBNP lowering from aliskiren. Viewing these data in isolation, one could speculate that AFF patients are potentially easier to decongest, and that this made significant incremental decongestion with aliskiren (i. However, the present data alone cannot prove these hypotheses.
Future clinical trial implications
With few notable exceptions, the last decade of HF trials has witnessed disappointing phase III results despite a myriad of promising phase II studies, highlighting a potential disconnect in the translational process and poor alignment between phase II and phase III trial endpoints. 4, 26, 27 In this regard, change from baseline in log-transformed NT-proBNP represents an increasingly utilized surrogate endpoint across the spectrum of early phase HF trials. 7, 23, 28, 29 The present analysis, with aliskiren as an example of an investigational HF therapy, demonstrates how AFF can further complicate interpretation of an NP-defined endpoint and generates the hypothesis that the ability of a study therapy to meet such an endpoint may depend on the prevalence of co-morbid AFF in the population. This finding supports the increasing attention towards the heterogeneity of the HHF syndrome as a key reason for the lack of successful drug discovery in this population. 27, 30, 31 Identifying surrogate endpoints for early phase HF trials is an important but challenging task. By definition, early stage trials are not powered for clinical endpoints, but rather are meant to inform pivotal phase III programmes where effects on 'hard' clinical outcomes are definitely assessed. To date, no surrogate endpoint for HF populations has been shown to be a perfect substitute for clinical events. 8 Presently, despite limitations and documented potential for discordance between NP-defined endpoints and clinical outcomes, change from baseline NT-proBNP may still be among the most practical endpoints for early phase trials. 3 However, the present results suggest a need to interpret such results with caution, paying particular attention to the AFF status of the population. Investigational therapies may exert varying efficacy by NT-proBNP level, which may track with AFF status. 32, 33 Recent trial designs have already begun to differentiate NP inclusion Figure 3 Longitudinal NT-proBNP level by atrial fibrillation/flutter (AFF) status (placebo patients only), depicted as univariate (A) and multivariate analysis (B). The y-axis represents the estimated NT-proBNP level in pg/mL, derived from exponentiation of the log-transformed NT-proBNP level at each time point. Multivariate analysis adjusted for age, gender, geographic region, ethnicity, ischaemic heart failure (HF) aetiology, NYHA functional class, medical history (prior HF hospitalization, hypertension, CAD, diabetes, chronic renal insufficiency), background therapies (ACE inhibitor/ARB, beta-blocker, mineralocorticoid receptor antagonist, digoxin, implantable cardioverter-defibrillator, CRT), body mass index, EF, systolic blood pressure, QRS duration, serum creatinine, and the following interactions with study visit: gender, ischaemic HF aetiology, NYHA functional class, beta-blocker, implantable cardioverter-defibrillator. AFFECG, atrial fibrillation/flutter on baseline electrocardiogram.
criteria by AFF status, and a similar rationale may be appropriate in defining NP-based endpoints. 5, 7, 32 Alternatively, it may be appropriate to pre-specify study stratification by AFF status, or by AFF status. Mounting evidence suggests that beta-blockers do not improve clinical outcomes in HF patients with concurrent AFF, adding further plausibility to the potential of AFF to influence surrogate endpoints such as NP level.
34,35
Limitations
Limitations of the present study should be acknowledged. First, absolute NT-proBNP levels decreased in both AFF and non-AFF groups over time and these trajectories must be interpreted in the context of ongoing patient death and loss to follow-up. Secondly, multivariate analysis for change from baseline NT-proBNP did not account for changes in time-dependent patient characteristics. However, this decision was pre-specified given the lack of data on follow-up rhythm status in order to ensure patient characteristics and AFF status were accurately aligned. Likewise, due to the lack of longitudinal ECG data, it was impossible to determine persistence of AFF during follow-up or to exclude potential crossover between AFF and non-AFF groups. For this reason, and to enrich the population with patients with perhaps a better likelihood of maintaining baseline rhythm during follow-up, patients with history of AFF but no AFF at baseline were excluded. Thirdly, despite rigorous multivariable modelling, this retrospective analysis is unable to test definitively cause-effect relationships, and inclusion of patients from a trial of HHF with reduced EF may limit the applicability of these findings to chronic ambulatory HF and HF with preserved EF populations. Fourthly, although the size of this cohort is comparable with multiple existing studies of AFF in HF populations, given the directionality of the HR and 95% CI, it is conceivable that AFF may have shown an independent association with CVM/HHF in a . 
Conclusions
This exploratory analysis within a HHF with reduced EF cohort suggests AFF may be a marker of a distinct longitudinal NT-proBNP trajectory, but found no significant difference in post-discharge NT-proBNP levels or clinical outcomes by AFF status after adjustment for patient characteristics. Aliskiren lowered follow-up NT-proBNP levels among non-AFF patients only. With aliskiren as a potential example, this study generates the hypothesis that the ability of a HF trial to meet an NT-proBNP-defined endpoint may be influenced by the prevalence of AFF in the population. These results should be validated in other HF populations and with other medications, but may be considered in the design of future HF drug development programmes.
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